Second, both ADAR1p110 and ADAR2 are phosphorylated by AKT kinase and this phosphorylation reduces A-to-I editing catalyzed by ADAR in the range of 50–100%.68,69 Selective AKT inhibitors have also been developed, including capivasertib, ipatasertib, and are in Phase I and Phase II clinical trials in fields of oncology.70 It is also tempting to speculate that inhibition of ADAR phosphorylation by AKT inhibitors may restore Alzheimer’s disease -dependent loss of A-to-I editing in HPC vasculature and if this may potentially slow or reverse cognitive decline in Alzheimer’s disease. The gene discussed is ADAR; the disease is early-onset autosomal dominant Alzheimer disease.